Mediators of apoptosis Fas and FasL predict disability progression in multiple sclerosis over a period of 10 years

Abstract

TNF-α, IL-12p35, IL-12p40, IL-4, IL-10, TGF-β1, CCR3, CXCR3, CCR5, Fas and FasL mRNA levels in PBMC of 25 multiple sclerosis (MS) patients were quantified at baseline by real-time PCR according to a post-hoc study design. The baseline values of the different markers were analysed with respect to their correlation with the increase in disability over a period of 10 years. High levels of Fas mRNA were associated with a favourable disease course in relapsing-remitting (RR) MS (R² = 0.74, P = 0.0001, n = 13), as measured by the Expanded Disability Status Scale (EDSS); high levels of FasL mRNA were associated with relatively mild disease progression (R² = 0.86, P = 0.0001, n = 12) in secondary progressive (SP) MS. These findings suggest that Fas-mediated apoptosis plays a major role in the mechanism underlying long-term disease progression in MS.

Keywords

apoptosis chemokines cytokines EDSS Fas MS

Get full access to this article

View all access options for this article.

References

Barkhof F. The clinico-radiological paradox in multiple sclerosis revisited . Curr Opin Neurol 2002; 15: 239-245 .

Kappos L , Stadt D , Keil W , Ratzka M , Heitzer T , Schneiderbanger-Grygier S. An attempt to quantify magnetic resonance imaging in multiple sclerosis-correlation with clinical parameters . Neurosurg Rev 1987; 10: 133-135 .

Kappos L , Moeri D , Radue EW , Schoetzau A , Schweikert K , Barkhof F , et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability impairment in multiple sclerosis: a meta-analysis . Lancet 1999; 353; 964-969 .

Rovaris M , Agosta F , Sormani MP , Inglese M , Martinelli V , Comi G , et al. Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study . Brain 2003; 126: 2323-2332 .

Brex PA , Ciccarelli O , O’Riordan JI , Sailer M , Thompson AJ , Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis . N Engl J Med 2002; 346: 158-164 .

Fisher E , Rudick RA , Cutter G , Baier M , Miller D , Weinstock-Guttman B , et al. Relationship between brain atrophy and disability: an 8-years follow-up study of multiple sclerosis patients . Mult Scler 2000; 6: 373-377 .

Santos AC , Narayanan S , de Stefano N , Tartaglia MC , Francis SJ , Arnaoutelis R , et al. Magnetization transfer can predict clinical evolution in patients with multiple sclerosis . J Neurol 2002; 249: 662-668 .

Kalkers NF , Bergers E , Castelijns JA , van Walderveen MA , Bot JC , Ader HJ , et al. Optimizing the association between disability and biological markers in MS . Neurology 2001; 57: 1253-1258 .

van Veen T , Kalkers NF , Crusius JB , van Winsen L , Barkhof F , Jongen PJ , et al. The FAS-670 polymorphism influences susceptibility to multiple sclerosis . J Neuroimmunol 2002; 128: 95-100 .

10.

Caillier S , Barcellos LF , Baranzini SE , Swerdlin A , Lincoln RR , Steinman L , et al. Osteopontin polymorphisms and disease course in multiple sclerosis . Genes Immunol 2003; 4: 312-315 .

11.

van Boxel-Dezaire AH , Hoff SC , van Oosten BW , Verweij CL , Dräger AM , Ader HJ , et al. Decreased IL-10 and increased IL-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis . Ann Neurol 1999; 45: 695-703 .

12.

Vogt MH , Lopatinskaya L , Smits M , Polman CH , Nagelkerken L. Elevated osteopontin levels in active relapsing-remitting multiple sclerosis . Ann Neurol 2003; 53: 819-822 .

13.

Lopatinskaya L , van Boxel-Dezaire AH , Barkhof F , Polman CH , Lucas CJ , Nagelkerken L. The development of clinical activity in relapsing-remitting MS is associated with a decrease of FasL mRNA and an increase of Fas mRNA in peripheral blood . J Neuroimmunol 2003; 138: 123-131 .

14.

Comi C , Leone M , Bonissoni S , DeFranco S , Bottarel F , Mezzatesta C , et al. Defective T cell Fas function in patients with multiple sclerosis . Neurology 2000; 55: 921-927 .

15.

Huang W-X , Huang MP , Gomes MA , Hillert J. Apoptosis mediators FasL and TRAIL are upregulated in peripheral blood mononuclear cells in MS . Neurology 2000; 55: 928-934 .

16.

Ichikawa H , Ota K , Iwata M. Increased Fas antigen on T cells in multiple sclerosis . J Neuroimmunol 1996; 71: 125-129 .

17.

Zipp F , Otzelberger K , Dichgans J , Martin R , Weller M. Serum CD95 of relapsing-remitting multiple sclerosis patients protects from CD95-mediated apoptosis . J Neuroimmunol 1998; 86: 151-154 .

18.

Kahl KG , Kruse N , Toyka KV , Rieckmann P. Serial analysis of cytokine mRNA profiles in whole blood samples from patients with early multiple sclerosis . J Neurol Sci 2002; 200: 53-55 .

19.

Makhlouf K , Weiner HL , Khoury SJ. Increased percentage of IL-12+monocytes in the blood correlates with the presence of active MRI lesions in MS . J Neuroimmunol 2001; 119: 145-149 .

20.

Balashov KE , Rottman JB , Weiner HL , Hancock WW. CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1a and IP-10 are expressed in demyelinating brain lesions . Proc Natl Acad Sci USA 1999; 96: 6873-6878 .

21.

Eikelenboom MJ , Killestein J , Izeboud T , Kalkers NF , van Lier RA , Barkhof F , et al. Chemokine receptor expression on T cells is related to new lesion development in multiple sclerosis . J Neuroimmunol 2002; 133: 225-232 .

22.

Baranzini SE , Elfstrom C , Chang SY , Butunoi C , Murray R , Higuchi R , et al. Transcriptional analysis of multiple sclerosis brain lesions reveals a complex pattern of cytokine expression . J Immunol 2000; 165: 6576-6582 .

23.

van Oosten BW , Lai M , Hodgkinson S , Barkhof F , Miller DH , Moseley IF , et al. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cMT412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial . Neurology 1997; 49: 351-357 .

24.

Lechner-Scott J , Kappos L , Hofman M , Polman CH , Ronner H , Montalban X , et al.

Can the Expanded Disability Status Scale be assessed by telephone?

Mult Scler 2003; 9: 154-159 .

25.

Pender MP. Genetically determined failure of activation-induced apoptosis of autoreactive T cells as a cause of multiple sclerosis . Lancet 1998; 351: 978-981 .

26.

Sharief MK. Impaired Fas-independent apoptosis of T lymphocytes in patients with multiple sclerosis . J Neuroimmunol 2000; 113: 236-243 .

27.

Zang YC , Kozovska MM , Hong J , Li S , Mann S , Killian JM , et al. Impaired apoptotic deletion of myelin basic protein-reactive T cells in patients with multiple sclerosis . Eur J Immunol 1999; 29: 1692-1700 .

28.

Achiron A , Gurevich M , Friedman N , Kaminski N , Mandel M. Blood transcriptional signatures of MS: unique gene expression of disease activity . Ann Neurol 2004; 55: 410-417 .

29.

Bechmann I , Steiner B , Gimsa U , Mor G , Wolf S , Beyer M , et al. Astrocyte-induced T cell elimination is CD95 ligand dependent . J Neuroimmunol 2002; 132: 60-65 .

30.

Magnus T , Chan A , Savill J , Toyka KV , Gold R. Phagocytic removal of apoptotic, inflammatory lymphocytes in the central nervous system by microglia and its functional implications . J Neuroimmunol 2002; 130: 1-9 .

31.

Kanwar JR , Kanwar RK , Krissansen GW. Simultaneous neuroprotection and blockade of inflammation reverses autoimmune encephalomyelitis . Brain 2004; 127: 1313-1331 .

32.

Todaro M , Zeuner A , Stassi G. Role of apoptosis in autoimmunity . J Clin Immunol 2004; 24: 1-11 .

33.

Banisor I , Kalman B. Bcl-2 and its homologues in the brain of patients with multiple sclerosis . Mult Scler 2004; 10: 176-181 .

34.

Wandinger KP , Lunemann JD , Wengert O , Bellmann-Strobl J , Aktas O , Weber A , et al. TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis . Lancet 2003; 361: 2036-2043 .

35.

Farrell R , Heaney D , Giovannoni G. Emerging therapies in multiple sclerosis . Expert Opin Emerg Drugs 2005; 10: 797-816 .